BR112014005406A2 - composição de vacina e respectivo uso - Google Patents

composição de vacina e respectivo uso

Info

Publication number
BR112014005406A2
BR112014005406A2 BR112014005406A BR112014005406A BR112014005406A2 BR 112014005406 A2 BR112014005406 A2 BR 112014005406A2 BR 112014005406 A BR112014005406 A BR 112014005406A BR 112014005406 A BR112014005406 A BR 112014005406A BR 112014005406 A2 BR112014005406 A2 BR 112014005406A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
vaccine
composition
Prior art date
Application number
BR112014005406A
Other languages
English (en)
Portuguese (pt)
Inventor
I Fattom Ali
R Baker James
Hamouda Tarek
Bitko Vira
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Publication of BR112014005406A2 publication Critical patent/BR112014005406A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112014005406A 2011-09-09 2012-09-10 composição de vacina e respectivo uso BR112014005406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161533062P 2011-09-09 2011-09-09
PCT/US2012/054395 WO2013036907A1 (fr) 2011-09-09 2012-09-10 Vaccin sous-unitaire contre le virus respiratoire syncytial (rsv) en nano-émulsion

Publications (1)

Publication Number Publication Date
BR112014005406A2 true BR112014005406A2 (pt) 2017-03-28

Family

ID=47830025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005406A BR112014005406A2 (pt) 2011-09-09 2012-09-10 composição de vacina e respectivo uso

Country Status (7)

Country Link
US (2) US9561271B2 (fr)
EP (2) EP3488863A1 (fr)
JP (2) JP6460792B2 (fr)
CN (1) CN104093421A (fr)
BR (1) BR112014005406A2 (fr)
CA (1) CA2848163C (fr)
WO (1) WO2013036907A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028738A1 (fr) * 2011-08-22 2013-02-28 Nanobio Corporation Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
CN104093421A (zh) * 2011-09-09 2014-10-08 纳诺碧欧公司 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗
WO2016057921A1 (fr) * 2014-10-10 2016-04-14 Baker Jr James R Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
US20190105385A1 (en) * 2016-03-23 2019-04-11 Intervet Inc. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection
US20200246449A1 (en) * 2017-05-03 2020-08-06 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
JP7317796B2 (ja) * 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
CN110833546B (zh) * 2018-08-17 2022-06-28 中国科学院分子细胞科学卓越创新中心 通佐溴胺在治疗胃癌中的用途
MX2021005767A (es) 2018-11-15 2021-09-21 Bluewillow Biologics Inc Composiciones de nanoemulsiones que tienen una permeabilidad mejorada.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5103497A (en) 1989-11-14 1992-04-07 Hicks John W Flying spot endoscope
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
ES2201551T3 (es) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2003519084A (ja) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
NZ512980A (en) 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP2545937A1 (fr) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Vaccins en nanoémulsion
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2006110699A1 (fr) 2005-04-11 2006-10-19 Nanobio Corporation Halogenures d'ammonium quaternaires pour le traitement de pathologies infectieuses
CA2618974C (fr) 2005-08-09 2014-01-28 Nanobio Corporation Compositions de nanoemulsions possedant une activite anti-inflammatoire
WO2008137747A1 (fr) * 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Compositions thérapeutiques à base de nanoémulsion et leurs procédés d'utilisation
CN102083415A (zh) 2008-04-18 2011-06-01 纳米生物公司 用于治疗疱疹病毒感染的方法
EP2293787A1 (fr) 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsions destinées à traiter des infections fongiques, et des infections provoquées par de la levure et de la moisissure
US20090269394A1 (en) 2008-04-25 2009-10-29 Nanobio Corporation Methods and compositions for treating onchomycosis
CA2826508C (fr) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Vaccins a nanoemulsion
EP2349209A2 (fr) 2008-09-26 2011-08-03 Nanobio Corporation Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
CA2750233A1 (fr) 2009-01-28 2010-08-05 Nanobio Corporation Composition pour le traitement et la prevention de l'acne, procedes de fabrication des compositions, et procedes d'utilisation associes
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
FR2960546B1 (fr) 2010-05-28 2012-07-13 Saint Gobain Rech Composition adhesive renfermant un polyester insature hydrosoluble ou dispersable dans l'eau et un monomere ethyleniquement insature, et utilisations.
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
EP2729169A1 (fr) 2011-07-06 2014-05-14 Nanobio Corporation Vaccin contre le virus syncytial respiratoire humain
CN104093421A (zh) * 2011-09-09 2014-10-08 纳诺碧欧公司 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗

Also Published As

Publication number Publication date
JP2017206514A (ja) 2017-11-24
JP6615151B2 (ja) 2019-12-04
CA2848163C (fr) 2020-10-27
EP2753354A1 (fr) 2014-07-16
JP2014526471A (ja) 2014-10-06
WO2013036907A1 (fr) 2013-03-14
CA2848163A1 (fr) 2013-03-14
US9561271B2 (en) 2017-02-07
EP3488863A1 (fr) 2019-05-29
US10596251B2 (en) 2020-03-24
CN104093421A (zh) 2014-10-08
US20130064867A1 (en) 2013-03-14
US20170360919A1 (en) 2017-12-21
EP2753354A4 (fr) 2015-04-15
JP6460792B2 (ja) 2019-01-30

Similar Documents

Publication Publication Date Title
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
BR112012021065A2 (pt) artigo de uso descartável
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
BR112013010988A2 (pt) composição fluída e uso
CO6831975A2 (es) Inmunoconjugados, composiciones para prepararlos, métodos para prepararlos y uso
BR112013007506A2 (pt) piridinonas/pirazinonas - métodos de criação e de uso
CO6930362A2 (es) Compuesto heterocíclico y su uso
BR112014023200A2 (pt) uso de uma composição
SMT201700110B (it) Composizione immunogena
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
BR112014005406A2 (pt) composição de vacina e respectivo uso
FI20116089L (fi) Järjestely ja laite
BR112014016635A2 (pt) composto, composição, e, uso de um composto
CO6781486A2 (es) Compuestos y su uso
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
CO6940436A2 (es) Composicion de control de fitoenfermedades y su uso
DK2343051T3 (da) Anti-cancer formulering
BRPI1011036A2 (pt) uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]